Shares of TG Therapeutics (NASDAQ: TGTX) gained over 60% in today’s session. This can be attributed to discussions between the company and the FDA about labeling for its multiple sclerosis therapy ublituximab.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Although ublituximab has not been approved yet, this is likely a good sign that approval chances are favorable.
Is TGTX Stock a Good Buy?
TGTX stock has a Moderate Buy consensus rating based on two Buys assigned in the past three months. The average TGTX stock price target of $18 implies 117.13% upside potential.
